Drug Profile
Osteoarthritis pain therapeutic - Eli Lilly and Company
Latest Information Update: 26 Oct 2012
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Musculoskeletal pain
Most Recent Events
- 17 Oct 2012 Discontinued - Phase-I for Musculoskeletal pain in USA (unspecified route)
- 15 Feb 2011 Phase-I clinical trials in Musculoskeletal pain in USA (unspecified route)